Selinexor found to increase progression-free survival for endometrial cancer with TP53 mutations

Maintenance therapy with selinexor provides durable survival benefits for endometrial cancer with TP53 mutations, according to a study presented during the July 2023 session of the American Society for Clinical Oncology Plenary Series…
Read More